SAN RAMON, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that the Company will present at the Credit Suisse Healthcare Conference in Scottsdale, AZ. During the presentation, Mr. Jonathan Rigby, President & CEO, will provide an overview and update on the Company's business.
Date: Monday, November 7, 2016
Time: 2:00 pm MT
Location: The Phoenician – Scottsdale, AZ
An audio webcast of the Company’s presentation will be available online at SteadyMed’s website www.steadymed.com. A replay of the presentation will be available for 90 days.
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Source: SteadyMed Therapeutics